San Diego
What San Diego's Wins Actually Anchor
Years in the government taught me that a good acronym is more art than science. The craft is a memorable handful of letters that carry meaning after the words behind them fall away.
Most people would not give the letters ASML a second look. But this summer, when the San Diego Regional EDC handed the Dutch company its "Life. Changing." Award, the recognition meant more for the region's economy and its place in critical global networks, than the headline let on.
The award is most immediately another mark of excellence for a company that has earned plenty. The more interesting story starts long before an award nomination, and it's an arc built on trust and partnership more than revenue. It is a significant thread in a larger story about the high-stakes markets where San Diego is drawing companies to invest more than money, and to stake their future intellectual property here.
ASML builds the only extreme-ultraviolet lithography machines in commercial production, the equipment the most advanced chips cannot be made without, and the light source at the heart of those machines is designed and built in Rancho Bernardo. ASML did not arrive with the 2022 trade mission. It has been deepening here since 2013, when it acquired Cymer for $3.7 billion. The EDC Life. Changing. Award recognizes a deeper partnership more than a decade long. I traced the full arc in our ASML case study.
The surface story is jobs and foreign investment. Both are real, and both matter. But a win like this is much more than an entry on a leaderboard. It is shared recognition and commitment between partners to build hard things.
What a company anchors here tells you more than why it says it came. ASML did not place a building or a tax position. It placed the part of its work that is hardest to move and most expensive to lose: its research, its people, its stake in an ecosystem it means to grow with.
That is the difference between a market companies purchase from and an ecosystem they build into. Partners aligned on values, and on how value can expand and deepen, do more than trade products. They co-locate the people who make the products possible, and the relationship compounds because both sides are building something meant to outlast any single deal.
ASML is not the only one. The same pattern is playing out across San Diego's life-sciences core. In February 2026, Novartis broke ground on a $1.1 billion global research center built to integrate with its research homes in Cambridge and Basel.
In May 2026, Pfizer opened a 230,000-square-foot oncology R&D hub on the Torrey Heights campus. In October 2025, Daiichi Sankyo chose San Diego for its third research institute outside Japan, after Boston and Munich. Different companies, different countries, but the same decision to anchor the research and the people here.
You could read each of these as a straightforward talent-and-real-estate calculation, and that math is real. But cost and convenience do not explain why a company plants the work it can least afford to lose, or builds it to integrate with home labs an ocean away.
That is the signal worth tracking. Not any single win, but a region that globally mobile companies keep choosing when they are investing in talent and trust, not just cost.
The work now is to see these moments clearly while they are still forming, and to keep building the relationships that turn a single decision into a durable advantage.